The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.
about
Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort.Frailty index of deficit accumulation and falls: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) Hamilton cohortComparison between frailty index of deficit accumulation and phenotypic model to predict risk of falls: data from the global longitudinal study of osteoporosis in women (GLOW) Hamilton cohort.Frailty Change and Major Osteoporotic Fracture in the Elderly: Data from the Global Longitudinal Study of Osteoporosis in Women 3-Year Hamilton Cohort.Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women.Concern and risk perception: effects on osteoprotective behaviour.Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW).Effective risk assessment tools for osteoporosis in the Indian menopausal female.When, where and how osteoporosis-associated fractures occur: an analysis from the Global Longitudinal Study of Osteoporosis in Women (GLOW)Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Risk factors for nonvertebral fracture in obese older womenBeneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.The Impact of Fracture Incidence on Health Related Quality of Life among Community-Based Postmenopausal WomenThe Relationship of Perceived Risk and Biases in Perceived Risk to Fracture Prevention Behavior in Older Women.Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in womenNon-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW).Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW).Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women.Predicting fractures in an international cohort using risk factor algorithms without BMD.Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)An increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW)Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).Obesity is not protective against fracture in postmenopausal women: GLOWIncrease in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women.Dairy products, dietary calcium and bone health: possibility of prevention of osteoporosis in women: the Polish experience.Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study.Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures.Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW).Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women.Education and information: important tools in assessing the risks and prevention of osteoporosis fractures.Insights from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Self-perception of fracture risk: what can it tell us?Bone Phenotype Assessed by HRpQCT and Associations with Fracture Risk in the GLOW Study.The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women.Differing risk profiles for individual fracture sites: evidence from the Global Longitudinal Study of Osteoporosis in Women (GLOW).Impact of osteoporosis and bone fracture on health-related quality of life in postmenopausal women.
P2860
Q30564085-D67A4390-6992-4419-A6EC-D8E62DC94A4CQ30828154-FF9D9A12-E883-409A-95FE-8F465A9F4CE9Q30909324-9F7689D1-3D46-4AE9-AFC2-C6818BF2AB63Q31019551-8A97A074-FCCD-45BE-90ED-BAEEE37D07F5Q33570080-C70017C2-82AB-47AD-BCBF-14941A5742DBQ34098487-F8137B30-DD96-4676-8D7C-B96F2DFF464AQ34234269-4AA5C851-43F9-4EDA-A332-9FEB39F783A7Q34472651-2829E321-FDF0-4741-8EE7-6B036F13DE5EQ35066049-3CA3B9CC-40C8-4ADC-828C-218D6AD935D4Q35070891-828A193D-5F3E-41D7-9D3E-1666C8C00E8CQ35077750-6431E993-46FE-430C-AAA5-3D396D53303EQ35137167-94F95298-2002-4871-978D-5ED1461F793DQ35681113-B675C0F8-7C36-4B72-A372-1DE518A82B06Q35947290-CFC81C0D-52FE-4BC6-8F21-487304390DF6Q36031550-8403F470-0A31-4AA4-9DCA-0B99F00F8E51Q36699092-CDC347E9-2F11-48B4-86A8-35F7EBF6D8B6Q36930046-5D981C63-5D99-4F4C-92C4-5FFF88D2D86BQ36930096-2D43BA22-C4EE-4CF9-997A-195DDF83AF15Q36931661-C40C2C7A-7399-46A1-9309-F4D2C5CD0EB6Q36939681-9BC3E2FE-6B1C-4D24-8A4C-6D9AF6D4753CQ36939692-A8563D58-A11A-43FE-AC7C-1C68C2AC774EQ36939699-DF253DCE-E7A9-4A02-A07C-424FD693C0D7Q36949759-8B0D6342-39F1-4393-88F8-8738EF60CB4EQ36949828-A5265ABC-96C9-407C-B435-1B7436FF3C82Q36980579-3676E6F3-A35C-4FBB-B606-881198B01CA2Q36980595-32FBF89A-0437-492F-AAEE-41DC4603BAF3Q37072078-0FE953F8-9D43-4BC3-BB3A-DEE3CC91BDFAQ37083822-6E5413B3-A3F3-41CC-A561-D4D0055E15EBQ37401906-737C6AF3-237D-4FE3-BF17-509683A08C8EQ37407747-CB85D12D-3E40-43E9-8513-5B3F88CB5676Q37568008-CF2923E8-FD84-4508-904F-0F6CC37568D5Q37640455-7C7B9D40-F9EE-4675-8ADC-A1AE74C20EE3Q37778395-5D5C1B12-A6A0-4E56-8A3F-897483451A97Q38206066-934A8C30-839F-4A90-AC4B-28D7112FA092Q38598416-13C7089A-6ABA-426D-B4E4-2FBB3514A05BQ40039554-7FD60735-8D1B-49BB-8081-1D3186F10902Q44892769-5D2CE90C-36CA-4B2A-879F-D3C9F3E6A509Q45000136-D1CA8E2F-F1B9-4025-B494-FD84C557FF6CQ45710580-71390D80-C7DC-45C8-9A69-94F1CA50E08DQ46115727-D15EA813-5E01-46B2-A0CE-9563E38CD14A
P2860
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The Global Longitudinal Study ...... ): rationale and study design.
@en
The Global Longitudinal Study of Osteoporosis in Women
@nl
type
label
The Global Longitudinal Study ...... ): rationale and study design.
@en
The Global Longitudinal Study of Osteoporosis in Women
@nl
prefLabel
The Global Longitudinal Study ...... ): rationale and study design.
@en
The Global Longitudinal Study of Osteoporosis in Women
@nl
P2093
P2860
P1476
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design
@en
P2093
F A Anderson
F H Hooven
J C Netelenbos
J Compston
J D Adachi
J Pfeilschifter
P2860
P2888
P304
P356
10.1007/S00198-009-0958-2
P407
P577
2009-05-26T00:00:00Z